BMC Musculoskeletal Disorders (Nov 2020)

A patients’ view of OA: the Global Osteoarthritis Patient Perception Survey (GOAPPS), a pilot study

  • Marianna Vitaloni,
  • Angie Botto-van Bemden,
  • Rosa Sciortino,
  • Xavier Carné,
  • Maritza Quintero,
  • Pedro Santos-Moreno,
  • Rolando Espinosa,
  • Oscar Rillo,
  • Jordi Monfort,
  • Francisco de Abajo,
  • Elizabeth Oswald,
  • Marco Matucci,
  • Patrick du Souich,
  • Ingrid Möller,
  • Montserrat Romera Baures,
  • Arlene Vinci,
  • Deborah Scotton,
  • Marco Bibas,
  • Guy Eakin,
  • Josep Verges

DOI
https://doi.org/10.1186/s12891-020-03741-0
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Globally, osteoarthritis (OA) is the third condition associated with disability. There is still poor treatment in OA but science holds the key to finding better treatments and a cure. It is essential to learn what’s important to patients from them to implement the most effective OA management. The OA Patients Task Force, conducted the Global OA Patient Perception Survey (GOAPPS)-the first global survey made by patients to analize the quality of life (QoL) & patient perceptions of care. The goal was to collect data on OA patients’ perception of OA to understand patients’ needs and expectations to improve OA management. Methods Observational, cross-sectional study by online survey data collection from six countries, translated into three languages. The questionnaire was comprised of 3 sections: patient demographics and clinical symptomology characteristics; relationship with physicians: perception of attention, treatment, and information provided; and OA impact on daily activity and QoL. The results of the survey were evaluated using the Limited Data Set. The survey results were analyzed using descriptive statistics to characterize the patients’ answers. Additionally, Cronbach’s alpha was calculated to determine internal consistency validity. Results A total of 1512 surveys were completed in 6 countries. 84.2% of respondents reported pain/tenderness and 91.1% experienced limitations to physical activities. 42.3% of patients were not satisfied with their current OA treatment. 86% had comorbidities, especially hypertension, and obesity. 51.3 and 78% would like access to additional drug or additional non-drug/non-surgical treatments respectively. 48.2% of patients perceived their QoL to be affected by OA. The Cronbach’s alpha was 0.61. Conclusions OA has a significant impact on patients’ daily activities and their desire to play an active role in managing this disease. Patients are seeking additional treatments, especially no pharmacological/no surgical treatments stressing the need for investing in clinical research, implementing OA preventive measures, and managing interventions to improve the healthcare value chain in OA.

Keywords